GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Great Novel Therapeutics Biotech & Medicals (ROCO:7427) » Definitions » Short-Term Debt

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Short-Term Debt : NT$0.62 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Great Novel Therapeutics Biotech & Medicals Short-Term Debt?

Great Novel Therapeutics Biotech & Medicals's Short-Term Debt for the quarter that ended in Dec. 2023 was NT$0.62 Mil.

Great Novel Therapeutics Biotech & Medicals's quarterly Short-Term Debt declined from Dec. 2022 (NT$0.83 Mil) to Jun. 2023 (NT$0.25 Mil) but then increased from Jun. 2023 (NT$0.25 Mil) to Dec. 2023 (NT$0.62 Mil).

Great Novel Therapeutics Biotech & Medicals's annual Short-Term Debt declined from Dec. 2021 (NT$0.86 Mil) to Dec. 2022 (NT$0.83 Mil) and declined from Dec. 2022 (NT$0.83 Mil) to Dec. 2023 (NT$0.62 Mil).


Great Novel Therapeutics Biotech & Medicals Short-Term Debt Historical Data

The historical data trend for Great Novel Therapeutics Biotech & Medicals's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Great Novel Therapeutics Biotech & Medicals Short-Term Debt Chart

Great Novel Therapeutics Biotech & Medicals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Short-Term Debt
Get a 7-Day Free Trial 0.19 0.08 0.86 0.83 0.62

Great Novel Therapeutics Biotech & Medicals Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.86 0.07 0.83 0.25 0.62

Great Novel Therapeutics Biotech & Medicals Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Great Novel Therapeutics Biotech & Medicals Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Great Novel Therapeutics Biotech & Medicals's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Business Description

Traded in Other Exchanges
N/A
Address
No.3, Park Street, Room WR-06, 17th Floor, Nangang District, Taipei, TWN, 11503
Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Headlines

No Headlines